Stock PTN PALATIN TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Palatin Technologies, Inc.

Equities

PTN

US6960775020

Real-time Estimate Cboe BZX
Other stock markets
 02:14:22 2024-05-02 pm EDT 		5-day change 1st Jan Change
2.125 USD +13.64% Intraday chart for Palatin Technologies, Inc. +22.67% -46.98%
Apr. 08 Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024 CI
Feb. 28 Sector Update: Health Care Stocks Decline Late Afternoon MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Palatin to Host Virtual KOL Event 'Beyond GLPs, the Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance' on May 8, 2024
AQ
PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024
AQ
PALATIN ANNOUNCES RESULTS OF PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE
AQ
PALATIN ANNOUNCES DATABASE LOCK FOR PL9643 MELODY-1 PIVOTAL PHASE 3 CLINICAL TRIAL IN PATIENTS WITH DRY EYE DISEASE
AQ
PALATIN ANNOUNCES $10 MILLION REGISTERED DIRECT OFFERING
AQ
PALATIN PROVIDES CORPORATE UPDATE AND HIGHLIGHTS STRATEGIC PRIORITIES FOR CALENDAR YEAR 2024
AQ
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
BU
PALATIN REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
AQ
PALATIN TO REPORT FIRST QUARTER FISCAL YEAR 2024 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON NOVEMBER 14, 2023
AQ
PALATIN ANNOUNCES CLOSING OF $5 MILLION REGISTERED DIRECT OFFERING
AQ
PALATIN ANNOUNCES POSITIVE PRECLINICAL DATA SHOWING SYNERGISTIC WEIGHT LOSS, INITIATING CLINICAL STUDY OF MELANOCORTIN 4 RECEPTOR AGONIST + GLP-1 IN OBESE PATIENTS
AQ
PALATIN PRESENTS DATA AT THE UNITED EUROPEAN GASTROENTEROLOGY WEEK 2023 CONFERENCE ON PL8177 ULCERATIVE COLITIS TREATMENT
AQ
PALATIN RECEIVES NOTICE OF NON-COMPLIANCE FROM NYSE AMERICAN
AQ
PALATIN REPORTS FOURTH QUARTER AND FISCAL YEAR ENDED 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
AQ
PALATIN TO REPORT FOURTH QUARTER AND FISCAL YEAR END 2023 RESULTS, TELECONFERENCE AND WEBCAST TO BE HELD ON SEPTEMBER 28, 2023
AQ
PALATIN INITIATES CLINICAL PROGRAM FOR BREMELANOTIDE CO-FORMULATED WITH A PDE5I FOR THE TREATMENT OF ED IN PATIENTS NON-RESPONSIVE TO PDE5I TREATMENT
AQ
PALATIN'S VYLEESI LICENSEE FOSUN PHARMA REPORTS FIRST COMMERCIAL SALE IN CHINA AND SOUTH KOREAN LICENSEE KWANGDONG PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 CLINICAL STUDY
AQ
PALATIN ANNOUNCES DIRECT-TO-CONSUMER TELEHEALTH PARTNERSHIP WITH UPSCRIPTHEALTH FOR VYLEESI
AQ
PALATIN TO PARTICIPATE IN CANACCORD GENUITY'S 43RD ANNUAL GROWTH CONFERENCE
AQ
PALATIN ANNOUNCES PRELIMINARY FOURTH QUARTER FISCAL 2023 VYLEESI PRODUCT REVENUE RESULTS
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PTN Stock
  4. News Palatin Technologies, Inc.
  5. Press Releases